Adverse prognostic markers included AGR2, IL6, MMP9, and TIMP1, whereas PAK3, Notch1, and B2M were linked to more prolonged survival or therapeutic responsiveness, underscoring the molecular heterogeneity of GBM. The gene discussed is AGR2; the disease is glioblastoma.